Do analysts rate PBM or SCYX?

SCYNEXIS has a consensus target price of $33.00, indicating a potential upside of 544.53%. Given SCYNEXIS's stronger consensus rating and higher possible upside, analysts plainly believe SCYNEXIS is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is PBM or SCYX more profitable?

Psyence Biomedical's return on equity of 0.00% beat SCYNEXIS's return on equity. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A SCYNEXIS N/A -44.15% -32.61%

Does the media favor PBM or SCYX?

In the previous week, SCYNEXIS had 3 more articles in the media than Psyence Biomedical. MarketBeat recorded 7 mentions for SCYNEXIS and 4 mentions for Psyence Biomedical. SCYNEXIS's average media sentiment score of 0.53 beat Psyence Biomedical's score of 0.38 indicating that SCYNEXIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Psyence Biomedical 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SCYNEXIS 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PBM or DWTX?

Dogwood Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 721.92%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, PBM or DWTX?

Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Psyence Biomedical N/A N/A -$6.94M $25.34 0.20 Dogwood Therapeutics N/A N/A -$34.26M -$8.95 N/A

Is PBM or DWTX more profitable?

Psyence Biomedical's return on equity of 0.00% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A Dogwood Therapeutics N/A -75.55% -40.28%

Do analysts recommend RYM or PBM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate PBM or VERU?

Veru has a consensus price target of $24.50, indicating a potential upside of 876.10%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Veru 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is PBM or VERU more profitable?

Psyence Biomedical's return on equity of 0.00% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A Veru N/A -47.58% -35.83%

Do analysts rate GRCE or PBM?

Grace Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 189.86%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Grace Therapeutics is more favorable than Psyence Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, GRCE or PBM?

Grace Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grace Therapeutics N/A N/A -$7.79M -$1.18 N/A Psyence Biomedical N/A N/A -$6.94M $25.34 0.20

Is GRCE or PBM more profitable?

Psyence Biomedical's return on equity of 0.00% beat Grace Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -36.11% -34.39% Psyence Biomedical N/A N/A N/A

Does the media favor GRCE or PBM?

In the previous week, Psyence Biomedical had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 4 mentions for Psyence Biomedical and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.91 beat Psyence Biomedical's score of 0.38 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Psyence Biomedical 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Psyence Biomedical (PBM) Competitors

$5.24 +0.08 (+1.47%)

As of 10:21 AM Eastern

Compare

PBM vs. SCYX, DWTX, RYM, VERU, and GRCE

Should you buy Psyence Biomedical stock or one of its competitors? Psyence Biomedical's main competitors and comparable companies include SCYNEXIS (SCYX), Dogwood Therapeutics (DWTX), RYTHM (RYM), Veru (VERU), and Grace Therapeutics (GRCE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Psyence Biomedical compare to SCYNEXIS?

Psyence Biomedical (NASDAQ:PBM) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

In the previous week, SCYNEXIS had 3 more articles in the media than Psyence Biomedical. MarketBeat recorded 7 mentions for SCYNEXIS and 4 mentions for Psyence Biomedical. SCYNEXIS's average media sentiment score of 0.53 beat Psyence Biomedical's score of 0.38 indicating that SCYNEXIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Psyence Biomedical	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SCYNEXIS	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Psyence Biomedical's return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
SCYNEXIS	N/A	-44.15%	-32.61%

Psyence Biomedical has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by company insiders. Comparatively, 4.1% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Psyence Biomedical has higher earnings, but lower revenue than SCYNEXIS. SCYNEXIS is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.20
SCYNEXIS	$20.60M	2.47	-$8.61M	-$2.09	N/A

SCYNEXIS has a consensus target price of $33.00, indicating a potential upside of 544.53%. Given SCYNEXIS's stronger consensus rating and higher possible upside, analysts plainly believe SCYNEXIS is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Psyence Biomedical and SCYNEXIS tied by winning 7 of the 14 factors compared between the two stocks.

How does Psyence Biomedical compare to Dogwood Therapeutics?

Psyence Biomedical (NASDAQ:PBM) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

77.4% of Psyence Biomedical shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 3.6% of Psyence Biomedical shares are held by insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Psyence Biomedical has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

In the previous week, Psyence Biomedical had 4 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 4 mentions for Psyence Biomedical and 0 mentions for Dogwood Therapeutics. Psyence Biomedical's average media sentiment score of 0.38 beat Dogwood Therapeutics' score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Psyence Biomedical	Neutral
Dogwood Therapeutics	Neutral

Dogwood Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 721.92%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.20
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A

Psyence Biomedical's return on equity of 0.00% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Dogwood Therapeutics	N/A	-75.55%	-40.28%

Summary

Psyence Biomedical beats Dogwood Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Psyence Biomedical compare to RYTHM?

RYTHM (NASDAQ:RYM) and Psyence Biomedical (NASDAQ:PBM) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

In the previous week, Psyence Biomedical had 4 more articles in the media than RYTHM. MarketBeat recorded 4 mentions for Psyence Biomedical and 0 mentions for RYTHM. Psyence Biomedical's average media sentiment score of 0.38 beat RYTHM's score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
RYTHM	Neutral
Psyence Biomedical	Neutral

RYTHM has a beta of 9.46, indicating that its stock price is 846% more volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market.

Psyence Biomedical has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. Psyence Biomedical's return on equity of 0.00% beat RYTHM's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Psyence Biomedical	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Psyence Biomedical has lower revenue, but higher earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28M	2.47	-$33.26M	-$10.53	N/A
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.20

6.0% of RYTHM shares are owned by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are owned by institutional investors. 3.5% of RYTHM shares are owned by insiders. Comparatively, 3.6% of Psyence Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Psyence Biomedical beats RYTHM on 10 of the 12 factors compared between the two stocks.

How does Psyence Biomedical compare to Veru?

Psyence Biomedical (NASDAQ:PBM) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Psyence Biomedical's return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Veru	N/A	-47.58%	-35.83%

Psyence Biomedical has higher earnings, but lower revenue than Veru. Veru is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.20
Veru	$16.89M	2.53	-$22.73M	-$0.69	N/A

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by insiders. Comparatively, 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Psyence Biomedical has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market. Comparatively, Veru has a beta of -1.21, meaning that its share price is 221% less volatile than the broader market.

Veru has a consensus price target of $24.50, indicating a potential upside of 876.10%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Psyence Biomedical had 4 more articles in the media than Veru. MarketBeat recorded 4 mentions for Psyence Biomedical and 0 mentions for Veru. Psyence Biomedical's average media sentiment score of 0.38 beat Veru's score of -0.35 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Psyence Biomedical	Neutral
Veru	Neutral

Summary

Psyence Biomedical beats Veru on 9 of the 14 factors compared between the two stocks.

How does Psyence Biomedical compare to Grace Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Psyence Biomedical (NASDAQ:PBM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Grace Therapeutics has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market.

Psyence Biomedical's return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-36.11%	-34.39%
Psyence Biomedical	N/A	N/A	N/A

Grace Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.20

6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are owned by institutional investors. 10.8% of Grace Therapeutics shares are owned by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Grace Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 189.86%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Grace Therapeutics is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Psyence Biomedical had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 4 mentions for Psyence Biomedical and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.91 beat Psyence Biomedical's score of 0.38 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Psyence Biomedical	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Psyence Biomedical beats Grace Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Psyence Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBM vs. The Competition

Export

Metric	Psyence Biomedical	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.07M	$12.20B	$7.13B	$13.32B
Dividend Yield	N/A	2.65%	2.53%	17.32%
P/E Ratio	0.21	802.22	274.76	26.04
Price / Sales	N/A	755.91	614.48	93.14
Price / Cash	N/A	15.08	27.22	34.69
Price / Book	0.71	10.47	11.13	6.35
Net Income	-$6.94M	$2.84B	$3.50B	$381.35M
7 Day Performance	-7.49%	-1.67%	-1.88%	-0.70%
1 Month Performance	15.33%	-5.70%	-6.20%	-4.58%
1 Year Performance	-73.98%	-2.27%	7.99%	1.51%

Psyence Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBM Psyence Biomedical	1.1305 of 5 stars	$5.24 +1.5%	N/A	-74.4%	$12.07M	N/A	0.21	12	Analyst Upgrade Gap Up
SCYX SCYNEXIS	3.0523 of 5 stars	$5.37 +8.7%	$33.00 +514.5%	-20.0%	$49.15M	$20.60M	N/A	29	Gap Up
DWTX Dogwood Therapeutics	3.1689 of 5 stars	$1.43 +5.9%	$12.00 +739.2%	-77.2%	$45.89M	N/A	N/A	8
RYM RYTHM	0.1438 of 5 stars	$20.00 -4.6%	N/A	-54.3%	$45.69M	$17.28M	N/A	141
VERU Veru	1.9173 of 5 stars	$2.54 -4.5%	$24.50 +864.6%	-33.9%	$45.35M	$16.89M	N/A	230	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBM) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Psyence Biomedical (PBM) Competitors

PBM vs. SCYX, DWTX, RYM, VERU, and GRCE

How does Psyence Biomedical compare to SCYNEXIS?

Summary

How does Psyence Biomedical compare to Dogwood Therapeutics?

Summary

How does Psyence Biomedical compare to RYTHM?

Summary

How does Psyence Biomedical compare to Veru?

Summary

How does Psyence Biomedical compare to Grace Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM vs. The Competition

Psyence Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Psyence Biomedical (PBM) Competitors

PBM vs. SCYX, DWTX, RYM, VERU, and GRCE

How does Psyence Biomedical compare to SCYNEXIS?

Does the media favor PBM or SCYX?

Is PBM or SCYX more profitable?

Which has more volatility & risk, PBM or SCYX?

Do institutionals and insiders believe in PBM or SCYX?

Which has higher earnings & valuation, PBM or SCYX?

Do analysts rate PBM or SCYX?

Summary

How does Psyence Biomedical compare to Dogwood Therapeutics?

Do insiders and institutionals hold more shares of PBM or DWTX?

Which has more risk and volatility, PBM or DWTX?

Does the media prefer PBM or DWTX?

Do analysts recommend PBM or DWTX?

Which has preferable valuation and earnings, PBM or DWTX?

Is PBM or DWTX more profitable?

Summary

How does Psyence Biomedical compare to RYTHM?

Does the media refer more to RYM or PBM?

Which has more volatility & risk, RYM or PBM?

Is RYM or PBM more profitable?

Do analysts recommend RYM or PBM?

Which has stronger earnings & valuation, RYM or PBM?

Do institutionals and insiders hold more shares of RYM or PBM?

Summary

How does Psyence Biomedical compare to Veru?

Is PBM or VERU more profitable?

Which has higher earnings and valuation, PBM or VERU?

Do insiders & institutionals have more ownership in PBM or VERU?

Which has more risk & volatility, PBM or VERU?

Do analysts rate PBM or VERU?

Does the media prefer PBM or VERU?

Summary

How does Psyence Biomedical compare to Grace Therapeutics?

Which has more volatility & risk, GRCE or PBM?

Is GRCE or PBM more profitable?

Which has higher earnings and valuation, GRCE or PBM?

Do insiders & institutionals have more ownership in GRCE or PBM?

Do analysts rate GRCE or PBM?

Does the media favor GRCE or PBM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM vs. The Competition

Psyence Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools